Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Pancreatic Neoplasms × selpercatinib × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1 Head & Neck 1 Gastrointestinal 1 Endocrine 1 Breast 1

Conditions

Thyroid Cancer, Papillary 1 Pancreatic Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Medullary 1 Breast Neoplasms 1

Interventions

zenocutuzumab 1 selpercatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Eli Lilly and Company

Approved for marketing

BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡